# KEYNOTE-966 (NCT04003636)

> Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: first-line advanced or unresectable biliary tract carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04003636
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Biliary Tract Carcinoma
- Interventions: Pembrolizumab; Gemcitabine; Cisplatin; Placebo
- Enrollment: 1069
- Primary outcome: Overall Survival (OS)

## Indexed commentary on KEYNOTE-966 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 73
- Podcasts: 49
- YouTube: 35

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=keynote-966-nct04003636

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04003636", "email": "<work email>"}; the inbox owner confirms by the emailed link.